Examination of hemodynamics of liver tumors such as hepatocellular carcinoma and hepatic parenchyma using intra-arterial contrast-enhanced ultrasonography

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1030210558

Enrollment

Registered

2022-01-19

Start date

2021-12-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma, liver cirrhosis

Interventions

We evaluate the effectiveness of intra-arterial contrast-enhanced ultrasonography for the hemodynamics of liver tumors such as hepatocellular carcinoma and the hepatic parenchyma.

D006528

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Based on the Evidence-based Clinical Practice Guidelines for hepatocellular carcinoma developed by the Japan Society of Hepatology, the cases in which transarterial chemoembolization or hepatic arterial infusion chemotherapy for hepatocellular carcinoma were selected and consent was obtained for this study.

Exclusion criteria

Exclusion criteria: Based on the same guidelines, the cases that are not indicated for transarterial chemoembolization or hepatic arterial infusion chemotherapy for hepatocellular carcinoma and for which consent cannot be obtained for this study. Excludes minors.

Design outcomes

Primary

Measure	Time frame
1. Recurrence rate and survival time after transarterial chemoembolization for hepatocellular carcinoma. 2. Adverse events Transarterial chemoembolization: a. Fever, b. Abdominal pain, c. Nausea, vomiting, d. Puncture bleeding, e. Renal disorder, f. Inguinal hematoma, g. Liver dysfunction, h. Liver abscess, i. Intratumoral hemorrhage Intra-arterial contrast-enhanced ultrasound: a. Diarrhea, b. Headache, c. Proteinuria, d. Neutrocytopenia, e. Rash, f. Dry mouth, g. Itching, h. Dyspnea, i. Low blood pressure	—

Measure

Time frame

1. Recurrence rate and survival time after transarterial chemoembolization for hepatocellular carcinoma. 2. Adverse events Transarterial chemoembolization: a. Fever, b. Abdominal pain, c. Nausea, vomiting, d. Puncture bleeding, e. Renal disorder, f. Inguinal hematoma, g. Liver dysfunction, h. Liver abscess, i. Intratumoral hemorrhage Intra-arterial contrast-enhanced ultrasound: a. Diarrhea, b. Headache, c. Proteinuria, d. Neutrocytopenia, e. Rash, f. Dry mouth, g. Itching, h. Dyspnea, i. Low blood pressure

—

Contacts

Public ContactKazue Shiozawa

Toho University Ohashi Medical Center

k.shio@med.toho-u.ac.jp+81-3-3468-1251

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026